Nutra Pharma Corporation - Product Pipeline Review - Q4 2010

GlobalData, November 2010, Pages: 62

Nutra Pharma Corporation – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Nutra Pharma Corporation - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Nutra Pharma Corporation - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Nutra Pharma Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Nutra Pharma Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Nutra Pharma Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Nutra Pharma Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Nutra Pharma Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Nutra Pharma Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Nutra Pharma Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Nutra Pharma Corporation and identify potential opportunities in those areas.

List of Tables
List of Figures
Nutra Pharma Corporation Snapshot
Nutra Pharma Corporation Overview
Key Information
Key Facts
Nutra Pharma Corporation – Research and Development Overview
Key Therapeutic Areas
Nutra Pharma Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Nutra Pharma Corporation – Pipeline Products Glance
Nutra Pharma Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Nutra Pharma Corporation–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Nutra Pharma Corporation – Drug Profiles
RPI-MN
Product Description
Mechanism of Action
R&D Progress
RPI-78
Product Description
Mechanism of Action
R&D Progress
RPI-MN
Product Description
Mechanism of Action
R&D Progress
RPI-78M
Product Description
Mechanism of Action
R&D Progress
Nutra Pharma Corporation – Pipeline Analysis
Nutra Pharma Corporation – Pipeline Products by Therapeutic Class
Nutra Pharma Corporation Pipeline Products By Target
Nutra Pharma Corporation – Pipeline Products by Molecule Type
Nutra Pharma Corporation – Company Statement
Nutra Pharma Corporation – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Aug 19, 2010: Nutra Pharma Begins Drug Registration Process In India For Nyloxin For Treatment Of Moderate To Severe Chronic Pain
Jun 23, 2010: Nutra Pharma Begins Drug Registration Process In Central America For Nyloxin Pain Reliever
Jun 23, 2010: Nutra Pharma Begins Drug Registration Process In Central America For Nyloxin Pain Reliever
Jun 23, 2010: Nutra Pharma Begins Drug Registration Process In Central America For Nyloxin Pain Reliever
May 25, 2010: Nutra Pharma Announces First Manufacturing Release Of Nyloxin Rx
Mar 30, 2010: Nutra Pharma Announces Availability Of Cobroxine In CVS
Jun 08, 2009: Nutra Pharma Announces Study Showing RPI-78 More Effective Than Morphine In the Treatment Of Moderate To Severe Pain
Feb 17, 2009: Nutra Pharma Announces Publication Of Positive Results Of ReceptoPharm Arthritis Study For RPI-78
Feb 17, 2009: Nutra Pharma Announces Publication Of Positive Results Of ReceptoPharm Arthritis Study For RPI-78
Feb 09, 2009: Nutra Pharma Subsidiary, ReceptoPharm, Files Patent Application For Novel Treatment Of Arthritis Using RPI-78
Financial Deals Landscape
Nutra Pharma Corporation, Deals Volume Summary, 2004 to YTD 2010
Nutra Pharma Corporation, Deals Summary By Region, 2004 to YTD 2010
Nutra Pharma Corporation, Deals Summary, 2004 to YTD 2010
Nutra Pharma Corporation Detailed Deal Summary
Asset Purchase
Nutra Pharma Acquires 11 Patents From NanoLogix
Acquisition
Nutra Pharma Acquires ReceptoPharm
Nutra Pharma Terminates Acquisition Of Portage BioMed
Equity Offering
Nutra Pharma Completes Private Placement Of $0.46 Million
Nutra Pharma Completes Private Placement Of $0.12 Million
Nutra Pharma Completes Private Placement Of $0.62 Million
Nutra Pharma Completes Private Placement Of $0.12 Million
Nutra Pharma Completes Private Placement Of $0.01 Million
Nutra Pharma Completes Private Placement Of $0.92 Million
Nutra Pharma Completes Private Placement Of $0.03 Million
Nutra Pharma Completes Private Placement Of $0.02 Million
Nutra Pharma Completes Private Placement Of $0.18 Million
Nutra Pharma Expands Licensing Agreement With NanoLogix
ReceptoPharm Forms Joint Venture With Zhong Xin Dong Tai
Nutra Pharma Enters Into Co-Marketing Agreement With NanoLogix
Nutra Pharma Enters Into Licensing Agreement With NanoLogix
Licensing Agreements
Nutra Pharma Enters Into Licensing Agreement With XenaCare
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Sports and Fitness Nutrition - Global Strategic Business Report
• Charter Schools - Global Outlook
• eLEARNING - Global Strategic Business Report
• Generic Defense Strategies: Lifecycle Management Strategies to Maximize Revenue in the Face of Growing Generic Competition
• Aerospace and Defense Industry - Global Strategic Business Report
• North America – Smart Weapons Markets and Technologies Outlook – 2013-2020
• Education Services - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Defense Robotics - Global Strategic Business Report
• The Global UAV Payload Market 2012-2022